Skip to Content

Conray-400 (iothalamate) Disease Interactions

There are 6 disease interactions with Conray-400 (iothalamate):


Iodinated radiopaque contrast agents (Includes Conray-400) ↔ hyperthyroidism

Severe Potential Hazard, Moderate plausibility. Applies to: Hyperthyroidism

Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium. Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.


Radiopaque contrast agents (Includes Conray-400) ↔ pheochromocytoma

Severe Potential Hazard, Moderate plausibility. Applies to: Pheochromocytoma

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.


Contrast agents (Includes Conray-400) ↔ sickle cell disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Sickle Cell Anemia

Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially. Caution is advised.


Intravascular contrast agents (Includes Conray-400) ↔ multiple myeloma

Moderate Potential Hazard, Moderate plausibility. Applies to: Multiple Myeloma

A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors. The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.


Iodinated contrast media (Includes Conray-400) ↔ renal disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Kidney Transplant, Hypertension, Liver Disease, Congestive Heart Failure

In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired. Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.


Iothalamate (Includes Conray-400) ↔ subarachnoid hemorrhage

Moderate Potential Hazard, Moderate plausibility. Applies to: Intracranial Hemorrhage

In patients with subarachnoid hemorrhage, a rare association between contrast administration and clinical deterioration, including seizures and death has been reported. Administration of intravascular iodinated contrast media such as iothalamate in these patients should be undertaken with caution.

Conray-400 (iothalamate) drug interactions

There are 262 drug interactions with Conray-400 (iothalamate)

Conray-400 (iothalamate) alcohol/food interactions

There is 1 alcohol/food interaction with Conray-400 (iothalamate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.